SII applies for emergency use authorization of Covid-19 vaccine candidate ‘Covishield’

The Serum Institute of India (SII) has filed an application to the Drugs Controller General of India (DCGI) for emergency use authorization of its potential Covid-19 vaccine candidate ‘Covishield’

SII’s application comes a day after Pfizer India urged for a similar permission for DCGI for Coronavirus vaccine.

A senior government official revealed to ANI, “SII has applied for emergency use authorization to DCGI. The application will be reviewed by the expert committee and after that final call will be taken.”

SII is the first Indian-origin company seeking for emergency usage approval for its Covid-19 vaccine created by it alongside the collaboration with international pharma giant AstraZeneca and Oxford University.

SII revealed earlier that ChAdOx1 nCov-2019 Covid-19 vaccine, developed by University of Oxford’s expertise teams, is supposedly inducing a strong immune response in the healthy adults in the range 56-69 and for seniors above 70 years of age.

Post the visit of PM Narendra Modi in the last month, SII CEO , Adar Poonawalla stated the indications recommend that Centre may buy 300 – 400 million doses by July 2021. Poonawalla further added SII has the capacity to produce 40 – 50 million doses of the vaccine on monthly basis and will extending the production up to 100 million doses of the vaccine monthly February onwards.

• Statewide Transport Workers’ Strike from Dec 31: Disruption in Bus Services Likely
• Mandya Kannada Sahitya Sammelana: Traffic Diversion on Bengaluru-Mysuru Expressway
• Ravichandran Ashwin Announces Sudden Retirement from International Cricket
• Free Cancer Vaccine Distribution in Russia from 2025: A Remarkable Medical Breakthrough
• Train Services Delayed Between Bengaluru-Mysuru: Introduction of New Train Numbers